AU760969B2 - System and method for evaluating agents which prevent oxidative damage - Google Patents
System and method for evaluating agents which prevent oxidative damage Download PDFInfo
- Publication number
- AU760969B2 AU760969B2 AU32388/00A AU3238800A AU760969B2 AU 760969 B2 AU760969 B2 AU 760969B2 AU 32388/00 A AU32388/00 A AU 32388/00A AU 3238800 A AU3238800 A AU 3238800A AU 760969 B2 AU760969 B2 AU 760969B2
- Authority
- AU
- Australia
- Prior art keywords
- fibroblast culture
- oxidative damage
- hypoxanthine
- elastin promoter
- human elastin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000004792 oxidative damage Effects 0.000 title claims description 18
- 238000000034 method Methods 0.000 title claims description 9
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 58
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 58
- 210000002950 fibroblast Anatomy 0.000 claims description 33
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 30
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 101000851054 Homo sapiens Elastin Proteins 0.000 claims description 20
- 102000054289 human ELN Human genes 0.000 claims description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 16
- 238000011830 transgenic mouse model Methods 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims 4
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 11
- 102000016942 Elastin Human genes 0.000 description 9
- 108010014258 Elastin Proteins 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- 102000016938 Catalase Human genes 0.000 description 8
- 108010053835 Catalase Proteins 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 206010051246 Photodermatosis Diseases 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000008845 photoaging Effects 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 206010068388 Actinic elastosis Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
WO 00/49876 PCT/US00/04438 1 SYSTEM AND METHOD FOR EVALUATING AGENTS WHICH PREVENT OXIDATIVE DAMAGE Background of the Invention Chronic sun exposure eventuates in wrinkling, sagging, pigmentary alterations, and skin cancers which are characteristic of sun-damaged skin, and collectively referred to as photoaging (Kligman., A. M. JAMA 210:2377-2380, 1969; Gilchrest, B.A. J. Am. Acad. Dermatol. 21:610-613, 1989). The major histopathologic alteration in the dermis of photoaged skin underlying the wrinkling, sagging and yellow discoloration characterizing photoaged skin is the accumulation of large amounts of abnormal elastic material, termed solar elastosis replacing the normally collagen-rich dermis (Mera et al. Br. J. Dermatol. 117:21-27, 1987; Bernstein et al. J. Invest. Dermatol. 103:182-186, 1994). One of the primary events in the generation of solar elastosis is elastin promoter activation (Bernstein et al. J. Invest.
Dermatol. 105, 269-273, 1995).
A transgenic mouse line expressing the human elastin promoter linked to a chloramphenicol acetyltransferase reporter gene (CAT) has been developed which models cutaneous photoaging in an in vivo and in vitro system (Bernstein et al.
J. Invest. Dermatol. 105, 269-273, 1995). Although phenotypically normal, the cells in these mice possess the human elastin promoter/CAT construct, allowing elastin promoter activity to be measured in response to stimuli such as ultraviolet radiation These mice, and fibroblasts cultures derived from their skin, have been demonstrated to provide a rapid and sensitive means of identifying compounds capable of inhibiting cutaneous photodamage (Bernstein et al.
J. Invest. Dermatol. 105, 269-273, 1995; Bernstein et al.
Photochem. Photobiol. 64:369-74, 1996; Bernstein et al. J. Am.
Acad. Dermatol. 37:725-729, 1997).
WO 00/49876 PCT/US00/04438 2 Among the various mechanisms by which UV damages skin is the generation of reactive oxygen species (Miyachi, Y. J.
Dermatol. Sci. 9:79-86, 1995). Reactive oxygen species may form immediately as a result of UV exposure, or result from the inflammatory response which often follows UV-induced injury. Although the erythema of a sunburn is clinical evidence of damage from UV, an inflammatory infiltrate may be evident histopathologically even in the absence of erythema, and may result in continued exposure of the dermis to free radicals, days after the UV-induced damage has occurred (Kligman, A. M. JAMA 210:2377-2380, 1969; Lavker et al. J. Am.
Acad. Dermatol. 32:53-62, 1995). The role of free radicals in cutaneous photodamage has been well documented (Ranadive, N.S. and Menon, I.A. Pathol. Immunopathol. Res. 5:118-139, 1986; Miyachi, Y and Imamura, S. Photodermatol. Photoimmunol.
Photomed. 7:49-50 1990; Miyachi, Y. J. Dermatol. Sci. 9:79-86, 1995; and Peak et al. Photochem. Photobiol. 54:197-203, 1991).
UV-induced free radical generation in skin has been demonstrated (Peak et al. Photochem. Photobiol. 54:197-203, 1991; and Norins, A.L. J. Invest. Dermatol. 39: 445-448, 1962). In addition, some enzymes which protect against oxidative damage, such as superoxide dismutase and catalase, are depleted after UV exposure (Pence, B.C. and Naylor, M.F.
J. Invest. Dermatol. 95:213-216, 1990; Maeda et al. Photochem.
Photobiol. 54:737-740, 1991; Shindo, Y and Hashimoto, T. J.
Dermatol. Sci. 14:225-232, 1997), and antioxidants that scavenge free radicals have demonstrated protection against UV (DeRios et al. J. Invest. Dermatol. 70:123-125, 1975; and Bissett et al. J. Soc. Cosmet. Chem. 43:85-92, 1992).
Investigators have recently demonstrated elastin mRNA production in response to free radicals generated using a xanthine and xanthine oxidase system in -vitro, providing evidence for the role of oxidative stress in the generation of solar elastosis (Kawaguchi et al. Free Radical Biol. Med.
23:162-165, 1997).
WO 00/49876 PCT/US00/04438 3 It has now been demonstrated that reactive oxygen species stimulate elastin production at the promoter level in fibroblasts derived from a transgenic mouse model of cutaneous photoaging. Further, the ability of an agent known to protect against oxidative damage to inhibit stimulation of elastin production in this system has also been demonstrated.
Accordingly, the present invention relates to an in vitro system and method for identifying agents capable of protecting against oxidative damage via a mouse fibroblast culture derived from a transgenic mouse capable of expressing human elastin promoter and a means for generating reactive oxygen species within the mouse fibroblast cultures.
Summary of the Invention An object of the present invention is to provide an in vitro system for identifying agents capable of inhibiting or preventing oxidative damage comprising a mouse fibroblast culture derived from a transgenic mouse capable of expressing human elastin promoter and a means for generating reactive oxygen species within the mouse fibroblast culture.
A method of identifying agents capable of inhibiting or preventing oxidative damage using this system is also provided.
Detailed Description of the Invention Oxidative damage may play a greater role in dermal, as compared to epidermal, damage from UV. Thus the generation of photoaging, clinically evident as wrinkling and sagging of skin, may result more from free radical-induced mechanisms than UV-induced skin cancers which originate in the epidermis.
Evidence for this includes the greater sensitivity of fibroblasts to free radical-induced damage as compared to keratinocytes (Applegate, L.A. and Frenk, E. Photodermatol.
Photoimmunol. Photomed. 11:95-101, 1995; Moysan et al.
WO 00/49876 PCT/US00/04438 4 Photodermatol. Photoimmunol. Photomed. 11:192-197, 1995; Masaki, H. and Sakurai, H. J. Dermatol. Sci. 14:207-216, 1997), and the fact that circulating inflammatory cells which produce free radicals course through the dermis and less frequently invade the epidermis. Also the longer wavelengths of UV, which produce less direct DNA damage (Setlow, R.B.
Science 153:379-386, 1966) but may exert their deleterious effects mainly through oxidative mechanisms, penetrate more deeply into skin, depositing much of their energy in the dermis. Thus, free radical mechanisms of damage may be the primary means by which UVA-induced photoaging takes place.
A number of effective sunscreens for blocking UVB are currently on the market, and increasing amounts of UVA protection are being incorporated into sunscreens to obtain higher sun protection factors. Further improvements are likely to result from incorporating effective free radical scavengers into currently available sunscreens. Accordingly, there is a need for a system of identifying agents which inhibit or prevent oxidative damage from the sun.
U.S. Patent 5,648,061 discloses a transgenic mouse model which permits investigation of human elastin promoter activity in response to ultraviolet irradiation both in vivo by direct irradiation of mouse skin, and in vitro by irradiation of dermal fibroblasts grown from skin explants.
It has now been demonstrated that generation of reactive oxygen species in these dermal fibroblasts via a hypoxanthine and xanthine oxidase system results in a 6-fold increase in elastin promoter activity. Further, this increase can be eliminated by the addition of catalase, an enzyme known to protect against oxidative damage. Accordingly, incorporation of a means for generating reactive oxygen species such as a hypoxanthine and xanthine oxidase system within these mouse fibroblast cultures results in a sensitive system for evaluating agents which may prevent oxidative damage. Using this system agents which may protect against the oxidative WO 00/49876 PCT/US00/04438 5 damage resulting from UV exposure may be rapidly screened, and promising candidates identified for further study and eventual incorporation into sunscreens.
A series of experiments were performed with this new system.
In a first set of experiments, the optimum time span for incubation of fibroblasts, derived from the skin of transgenic mice, with a hypoxanthine and xanthine oxidase system was determined by exposing cells to a hypoxanthine and xanthine oxidase system for increasing amounts of time, and determining CAT activity as outlined in Example 3 after a 24 hour incubation. CAT activity increased steadily until a peak occurred after 90 minutes of incubation. Longer incubation times resulted in excessive cell toxicity and a corresponding decrease in CAT activity. Thus, a 90 minute incubation time for cells to be in contact with hypoxanthine and xanthine oxidase was selected for further studies.
The addition of hypoxanthine and xanthine oxidase to fibroblast cultures for 90 minutes increased human elastin promoter activity as determined by CAT assay to 6.0 0.6-fold (mean sem) that of untreated control cells. The addition of 10,000 U/ml of catalase just prior to hypoxanthine and xanthine oxidase exposure fully eliminated this increase.
Catalase-treated cells exposed to hypoxanthine and xanthine oxidase demonstrated no increase over control cells, with a mean of 1.0 0.1-fold of untreated controls. Trypan blue exclusion demonstrated less than 15% toxicity in cells treated with hypoxanthine/xanthine oxidase and hypoxanthine/xanthine oxidase plus catalase.
Accordingly, these mouse fibroblast cultures which express the human elastin promoter and comprise a means for generation of reactive oxygen species such as a hypoxanthine and xanthine oxidase system provide a useful system for identifying agents capable of protecting against oxidative damage. Test agents suspected of providing protection against oxidative damage can be added to the mouse fibroblast culture prior to addition of the means for generation of reactive oxygen species. The means for generating reactive oxygen species is then added and human elastin promoter activity is determined in the mouse fibroblast culture after a selected time period, preferably 90 minutes for a hypoxanthine and xanthine oxidase system.
In a preferred embodiment, elastin promoter activity is determined by measuring expression of the reporter gene, i.e. the CAT activity, of the mouse fibroblast culture. Human elastin promoter activity in the mouse fibroblast culture exposed to the test agent is then compared to elastin promoter activity in a control fibroblast culture not exposed to the test agent but still exposed to the means for generating reactive oxygen species. Agents providing protection against oxidative damage are identified as those test agents which decrease human elastin promoter activity in the mouse fibroblast culture exposed to the test agent and the means for generating reactive oxygen species as compared to the control fibroblast culture.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
:"Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
The following nonlimiting examples are provided to further illustrate the present invention.
Examples Example 1: Fibroblast Cultures Expressing the Human Elastin Promoter Fibroblasts derived from the skin of a homozygous line of transgenic mice expressing the 5.2-kb human elastin promoter, linked to a CAT reporter gene which enables measurement of elastin promoter activation, as previously described (Bernstein et al. J. Invest. Dermatol. 105, 269-273, 1995; and Bernstein et al. Photochem Photobiol., 64:369-74, 1996) were utilized.
6A Although phenotypically normal, these mice express the human elastin promoter when assayed for CAT activity (Hsu-Wong et al, J. Biol. Chem.
269:18072-18075, WO 00/49876 PCT/US00/04438 7 1994; Bernstein et al. J Invest Dermatol 105, 269-273, 1995; and Bernstein et al. Photochem Photobiol 64:369-74, 1996).
Fibroblast cultures were established from the skin of transgenic mice by explanting tissue specimens onto plastic tissue culture dishes and allowing cells to migrate to the area of the dish surrounding the explants. The primary cultures were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM Lglutamine and antibiotics, at 37 0 C. The primary cell cultures were passaged by trypsinization, and the subcultures in passages three or four were exposed to hypoxanthine/ xanthine oxidase.
Example 2: Exposure to free radicals generated by hypoxanthine/xanthine oxidase DMEM with 10% FCS was removed, cells were rinsed in phosphate buffered saline (PBS), and DMEM was replaced without the addition of FCS. Both 500 AM hypoxanthine (Sigma Chemical Co., St. Louis, MO) and 80 mU/ml xanthine oxidase (Sigma Chemical Co., St. Louis, MO) were then added to fibroblast cultures which were incubated for 90 minutes at 37 0 C. The concentrations of hypoxanthine and xanthine oxidase were selected based on previous work by Mitchell et al.
(Biochemistry 29:2802-2807, 1990). The optimum time span for incubation of cells with hypoxanthine/xanthine oxidase was determined by exposing cells to hypoxanthine/xanthine oxidase for 15, 30, 60, 90 and 120 minutes and determining CAT activity as outlined in Example 3. After exposure to hypoxanthine/xanthine oxidase, cells were rinsed in PBS and incubated in DMEM with FCS for 24 hours, which is the time maximal promoter activation was determined to occur after exposure to hypoxanthine/xanthine oxidase and then harvested for determination of CAT activity (Hsu-Wong et al. J. Biol.
Chem. 269: 18072-18075, 1994; Bernstein et al. J Invest WO 00/49876 PCT/US00/04438 8 Dermatol 105, 269-273, 1995; and Bernstein et al. Photochem Photobiol 64:369-74, 1996). Control cells were treated in an identical fashion without the addition of hypoxanthine/xanthine oxidase.
In addition to hypoxanthine/xanthine oxidase treatment alone, cells were also treated with hypoxanthine/xanthine oxidase plus 10,000 U/ml of catalase (Sigma Chemical Co., St.
Louis, MO) co-incubated for 90 minutes, and harvested as outlined above 24 hours following treatment. Fibroblasts from mice representing the same litter were used for any given experiment. Four dishes of cells were used for each experimental condition (control, hypoxanthine/xanthine oxidase, and hypoxanthine/xanthine oxidase+catalase), and experiments were repeated in duplicate, yielding a total of eight values for each experimental condition.
The effect of hypoxanthine/xanthine oxidase and hypoxanthine/xanthine oxidase+catalase on cell viability was determined using the trypan blue (Sigma Chemical Co., St.
Louis, MO) exclusion method (Ausubel et al. Short protocols in molecular biology. John Wiley Sons, Inc., 2nd ed., New York, 1992 p.11- 24 and a paired t-test analysis was performed for statistical evaluation of the data.
Example 3: CAT Assay To measure the expression of the human elastin promoter/CAT reporter gene construct in the skin of transgenic mice and in fibroblast cultures established from these animals, CAT activity was determined. For extraction of the CAT from skin, the specimens were homogenized in 0.25 Tris- HC1, pH 7.5, using a tissue homogenizer (Brinkmann Instruments, Inc. Westbury, NY) The homogenates were centrifuged at 10,000 X g for 15 minutes at 4 0 C and the protein concentration in the supernatant determined by a commercial protein assay kit (Bio-Rad Laboratories, Richmond, CA). Aliquots of the supernatant containing 100 Ag of protein WO 00/49876 PCT/USOO/04438 -9were used for assay of CAT activity by incubation with 4
C]
chloramphenicol in accordance with well-known procedures. The acetylated and non-acetylated forms of radioactive chloramphenicol were separated by thin-layer chromatography and CAT activity was determined by the radioactivity in the acetylated forms as a percent of the total radioactivity in each sample.
Claims (6)
1. An in vitro system for identifying agents capable of inhibiting or preventing oxidative damage comprising: a mouse fibroblast culture derived from a transgenic mouse capable of expressing human elastin promoter; and a chemical means for generating reactive oxygen species within the mouse fibroblast culture.
2. An in vitro system according to claim 1, wherein the chemical means for generating reactive oxygen species is a hypoxanthine and xanthine oxidase system.
3. A method for identifying agents capable of inhibiting or preventing oxidative damage comprising: adding a test agent suspected of providing protection against oxidative damage to a mouse fibroblast culture derived from a transgenic mouse capable of expressing human elastin promoter; adding a chemical means for generation of reactive oxygen species to the mouse fibroblast culture; determining human elastin promoter activity in the mouse fibroblast culture exposed to the test agent after a selected time period; and comparing the determined human elastin promoter activity in the mouse fibroblast culture exposed to the test agent to human elastin promoter activity in a control fibroblast culture wherein a decrease in the determined human elastin promoter activity is indicative of the test agent inhibiting or preventing oxidative damage.
4. A method according to claim 3, wherein the chemical means for generation of reactive oxygen species is a hypoxanthine and xanthine oxidase system.
5. An in vitro system according to claim 1 substantially as hereinbefore described with reference to any one of the Examples. 11
6. A method according to claim 3 substantially as hereinbefore described with reference to any one of the Examples. Dated this nineteenth day of February 2003 Charles River Laboratories, Inc. Patent Attorneys for the Applicant: F B RICE CO r
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12141899P | 1999-02-23 | 1999-02-23 | |
| US60/121418 | 1999-02-23 | ||
| PCT/US2000/004438 WO2000049876A1 (en) | 1999-02-23 | 2000-02-22 | System and method for evaluating agents which prevent oxidative damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3238800A AU3238800A (en) | 2000-09-14 |
| AU760969B2 true AU760969B2 (en) | 2003-05-22 |
Family
ID=22396604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU32388/00A Ceased AU760969B2 (en) | 1999-02-23 | 2000-02-22 | System and method for evaluating agents which prevent oxidative damage |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1162886A4 (en) |
| JP (1) | JP2002541774A (en) |
| AU (1) | AU760969B2 (en) |
| CA (1) | CA2362904A1 (en) |
| WO (1) | WO2000049876A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405081B2 (en) * | 2001-02-05 | 2008-07-29 | Pan Shen Q | Methods and kits for identifying scavengers of reactive oxygen species (ROS) |
| US20080312128A1 (en) * | 2005-04-29 | 2008-12-18 | Edward Chaum | Cellular Biomarker Antioxidant Assay and Uses Thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996037237A1 (en) * | 1995-05-24 | 1996-11-28 | Thomas Jefferson University | An in vivo and in vitro model of cutaneous photoaging |
| US5648061A (en) * | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
| US5840734A (en) * | 1997-05-06 | 1998-11-24 | Thomas Jefferson University | Use of tempol in the prevention of photoaging |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066327A (en) * | 1997-12-17 | 2000-05-23 | Color Access, Inc. | Antioxidant mixture |
-
2000
- 2000-02-22 EP EP00910266A patent/EP1162886A4/en not_active Withdrawn
- 2000-02-22 AU AU32388/00A patent/AU760969B2/en not_active Ceased
- 2000-02-22 WO PCT/US2000/004438 patent/WO2000049876A1/en not_active Application Discontinuation
- 2000-02-22 JP JP2000600496A patent/JP2002541774A/en active Pending
- 2000-02-22 CA CA002362904A patent/CA2362904A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996037237A1 (en) * | 1995-05-24 | 1996-11-28 | Thomas Jefferson University | An in vivo and in vitro model of cutaneous photoaging |
| US5648061A (en) * | 1995-05-24 | 1997-07-15 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
| US5840734A (en) * | 1997-05-06 | 1998-11-24 | Thomas Jefferson University | Use of tempol in the prevention of photoaging |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2362904A1 (en) | 2000-08-31 |
| EP1162886A1 (en) | 2001-12-19 |
| AU3238800A (en) | 2000-09-14 |
| WO2000049876A1 (en) | 2000-08-31 |
| EP1162886A4 (en) | 2003-02-12 |
| JP2002541774A (en) | 2002-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barja | Endogenous oxidative stress: relationship to aging, longevity and caloric restriction | |
| US20120263663A1 (en) | Compositions and methods for prevention of photoaging | |
| US5840734A (en) | Use of tempol in the prevention of photoaging | |
| US5648061A (en) | In vivo and in vitro model of cutaneous photoaging | |
| AU761674B2 (en) | Use of nitroxides in wound healing and in the prevention of photodamage | |
| Maeda et al. | Effects of chronic exposure ultraviolet‐A including 2% ultraviolet‐B on free radical reduction systems in hairless mice | |
| AU760969B2 (en) | System and method for evaluating agents which prevent oxidative damage | |
| US6753146B1 (en) | System and method for evaluating agents which prevent oxidative damage | |
| AU761728B2 (en) | An (in vivo) and (in vitro) model for cutaneous photoaging and oxidative damage | |
| Bernstein | Reactive oxygen species activate the human elastin promoter in a transgenic model of cutaneous photoaging | |
| AU720476B2 (en) | Use of tempol in the prevention of photoaging | |
| WO1996037237A1 (en) | An in vivo and in vitro model of cutaneous photoaging | |
| US20060029555A1 (en) | Compositions and methods for prevention of photoaging | |
| US6018098A (en) | In vivo and in vitro model of cutaneous photoaging | |
| CA2253187C (en) | Use of tempol in the prevention of photoaging | |
| Lake | Individual variation in DNA repair in human peripheral blood monocytes | |
| Rake | Nucleosome unit repeat size in aneuploid mice | |
| Vivo | Photoaging is Associated with Protein Oxidation in Human |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CHARLES RIVER LABORATORIES, INC. Free format text: THE FORMER OWNER WAS: ERIC F BERNSTEIN |
|
| FGA | Letters patent sealed or granted (standard patent) |